FEATURE ARTICLES

How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever
How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever

The story of how Juan Ramón Alaix was groomed for his CEO role and how Zoetis turned into the world’s largest publicly traded animal health company.

More featured articles

ALSO IN THIS MONTH'S ISSUE

  • Path Forward On Obamacare Replacement?
    Path Forward On Obamacare Replacement?

    After the House of Representatives passed The American Health Care Act — the bill that would replace Obamacare — by a razor-thin margin, consideration moved to the Senate, where Republicans have only two votes to spare to secure passage.

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • The Power of Small Wins — And How to Keep Them Going
    The Power of Small Wins — And How to Keep Them Going

    Because drug R&D is likely to remain difficult even as technology advances, the challenge for you, as a leader, is this: How do you maintain the motivation of talented researchers, young and old, when progress is slow?

  • How NYC Is Building A World-Class Life Science Hub
    How NYC Is Building A World-Class Life Science Hub

    A life science ecosystem is taking root in New York City that in 10 years’ time could vie with Boston and San Francisco as measured by the number of jobs and startups, funding resources, or high science ideas.

  • Bridging The Gap Between Academia, Small Biotechs, And Industry
    Bridging The Gap Between Academia, Small Biotechs, And Industry

    Academia and biotech have long been sources of innovation for the pharmaceutical industry, and this is increasingly important for Big Pharmas that want to prop up flagging pipelines or boost particular areas of focus.

More from Life Science Leader

SPECIAL EDITION: 2017 CRO LEADERSHIP AWARDS

 

Read all the exclusive content — including who our CRO award winners are this year — in the 2017 CRO Leadership Awards Special Edition.

 

 

WEB-EXCLUSIVE EDITORIAL

  • Making Last-Minute Serialization Preparations For The Nov. 2017 DSCSA Deadline
    Making Last-Minute Serialization Preparations For The Nov. 2017 DSCSA Deadline

    Starting on Nov. 27, 2017, pharmaceutical manufacturers are required to begin marking all saleable units and homogeneous cases of prescription drugs with a unique serial identification code (product identifier), as stipulated by the Drug Supply Chain Security Act. Many drug makers have been preparing for this so-called “serialization” deadline for years by implementing new processes and systems in their internal operations, or by ensuring efficient transfer of serialization data from their contract manufacturing/packaging partners. However, some manufacturers — in particular, smaller or virtual firms — are now engaged in a mad scramble to meet all the requirements of the deadline.

  • 3 Hacks For High CRA Retention
    3 Hacks For High CRA Retention

    According to the 2016 California Workforce Trends in the Life Science Industry, there were 16,000 statewide life science job postings during the calendar year; 2,732 of those jobs related to clinical trials. In 2015, over 85 percent of life science positions required a minimum of a bachelor’s degree. Hiring managers expect the strong demand for talent to continue until 2018.

  • Navigating The Increasingly Complex World Of Orphan Drug Commercialization
    Navigating The Increasingly Complex World Of Orphan Drug Commercialization

    Prior to the passage of the Orphan Drug Act of 1983, a meager 38 orphan drugs were approved, corresponding to an approved drug for less than 1 percent of an estimated 7,000 orphan diseases.

  • What Is Supply Chain Capacity In 2017?
    What Is Supply Chain Capacity In 2017?

    “Capacity” for outsourcing development and manufacturing has mostly been defined by a strict calculation of how much material a facility (or facilities) can output over a period of time. Executives from companies like MedImmune and Merck tell us why, unfortunately, that definition doesn’t work anymore.

  • The Importance Of Harmonizing Tariff Classification For Clinical Trial Supplies
    The Importance Of Harmonizing Tariff Classification For Clinical Trial Supplies

    Trade tariffs can significantly impact the cost of importing and exporting investigational products and ancillary supplies for clinical trials. As such, it is important that companies consider harmonized tariff classification to ensure no money is left on the table.

More web-exclusive editorial

BEYOND THE PRINTED PAGE

  • What Would 6 Industry Icons Do Differently If Given The Chance To Be CEO Again

    In the July 2017, Life Science Leader magazine we will be publishing the article — Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders. The story features six former CEOs: Mike Bonney (Cubist); Hank McKinnell, Ph.D., (Pfizer); Francois Nader, M.D., (NPS Pharmaceuticals); David Pyott (Allergan); Stephen Sherwin, M.D., (Cell Genesys); and Henri Termeer (Genzyme). As each of these executive was gracious enough to give us an hour of their time, we encountered a slight problem — too many great insights to be included within all the pages of a print publication.

  • Why Would Human Health Companies Want To Partner With Zoetis?

    When Zoetis, the former animal health business unit of Pfizer, was spun off as an independent company via an IPO in February 2013 (see Life Science Leader’s June 2017 cover feature), overnight it became the world’s largest publically traded animal health company. And while no longer part of one of the largest human health companies in the world, this doesn’t mean that a company focused on developing products just for animals isn’t interested in collaborating with biopharmas dedicated to creating therapeutics for people. Scott Brown, D.V.M., Ph.D., is the executive responsible for brokering such collaborations. The VP of external innovation elaborates on some of the challenges faced by Zoetis post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal–health-focused company like Zoetis.

  • IO KOLs Speak On

    More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.

More Beyond The Printed Page Articles

LIFE SCIENCE TRAINING INSTITUTE COURSES

Making Training Stick: Ensuring Your GMP & Task Training Is Effective June 22, 2017
1pm-2:30pm EDT, Online Training
How To Establish The Number of Runs Required For Process Validation June 28, 2017
1:00 - 2:00 PM EDT, Online Training
CRO Oversight Post ICH GCP E6 (R2) Addendum July 10, 2017
11:00am- 12:00pm EDT, Online Training
Monitoring Plan Development: Post ICH GCP E6 (R2) Addendum August 25, 2017
11:00am- 12:00pm EDT, Online Training
More training courses

JUNE 2017 DIGITAL EDITION

2017 CRO AWARDS SPECIAL EDITION

2017 CMO AWARDS SPECIAL EDITION

BLOGS

  • How Has Biopharma Arrived At Its Current Lose-Lose Situation?
    How Has Biopharma Arrived At Its Current Lose-Lose Situation?

    Drug Sales Reel Amid Probe Into Charities. This was the headline of Jonathan Rockoff’s June 12, 2017, Wall Street Journal article that points out how sales for two U.S. “blockbuster prostate-cancer drugs” (i.e., J&J’s Zytiga and Pfizer’s Xtandi) were down (i.e., 14 and 11 percent respectively) for the first quarter from a year previous. Apparently there are two contributing factors that explain this drop in sales — a charitable-giving federal investigation, and how the companies have responded to patients in need.

  • 3 Can’t Miss Educational Sessions At BIO 2017
    3 Can’t Miss Educational Sessions At BIO 2017

    As we get closer to one of our industry’s biggest annual gatherings, the BIO International 2017 Convention in San Diego, June 19 – 22, I have begun to pin down my schedule for which educational sessions I plan to attend. For me, this has always been a challenge, as BIO has so much great educational content. And with many of the educational sessions overlapping, I find I have to pick and choose where I want to be, often with at least two options from which to pick.

More blogs

@LIFESCILEADER1

 UPCOMING EVENTS

Making Training Stick: Ensuring Your GMP & Task Training Is Effective June 22, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Introductory Rate
Alice June 26 - 28, 2017
Bangkok, CA
FDA GMP Inspections – Proven Preparation & Survival Techniques June 27, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Biomanufacturing Strategy Meeting USA 2017 June 27, 2017
HILTON BOSTON LOGAN AIRPORT, MA
More events